Effectiveness of intravenous immunoglobulin alone and intravenous immunoglobulin combined with high-dose aspirin in the acute stage of Kawasaki disease: study protocol for a randomized controlled trial

Ho-Chang Kuo, Mindy Ming-Huey Guo, Mao-Hung Lo, Kai-Sheng Hsieh, Ying-Hsien Huang, Ho-Chang Kuo, Mindy Ming-Huey Guo, Mao-Hung Lo, Kai-Sheng Hsieh, Ying-Hsien Huang

Abstract

Background: Kawasaki disease (KD) is an acute febrile systemic vasculitis most commonly seen in children under 5 years old. High-dose aspirin is often administered, but the duration of such treatment varies. Many centers reduce the aspirin dose once the patient is afebrile, even before treating said patient with intravenous immunoglobulin (IVIG). However, a randomized controlled trial regarding high-dose aspirin in the acute stage of KD has not previously been carried out.

Methods/design: This trial has been designed as a multi-center, prospective, randomized controlled, evaluator-blinded trial with two parallel groups to determine whether IVIG alone as the primary therapy in acute-stage KD is as effective as IVIG combined with high-dose aspirin therapy. The primary endpoint is defined as coronary artery lesion (CAL) formation at 6-8 weeks. Patients meeting the eligibility criteria are randomly assigned (1:1) to a test group (that receives only IVIG) or a standard group (that receives IVIG plus high-dose aspirin). This clinical trial is conducted at three medical centers in Taiwan.

Discussion: Since high-dose aspirin has significant anti-inflammatory and anti-platelet functions, it does not appear to affect disease outcomes. Furthermore, it can decrease hemoglobin levels. Therefore, we have initiated this randomized controlled trial to evaluate the necessity of high-dose aspirin in the acute stage of KD.

Trial registration: Kawasaki Disease Center, Kaohsiung Chang Gung Memorial Hospital, Taiwan. ClinicalTrials.gov Identifier: NCT02951234. Release Date: November 3, 2016.

Keywords: Coronary artery lesions; Intravenous immunoglobulin; Kawasaki disease; Randomized clinical trial.

Conflict of interest statement

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

    1. Kawasaki T. Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children. Arerugi. 1967;16(3):178–222.
    1. Wang CL, Wu YT, Liu CA, Kuo HC, Yang KD. Kawasaki disease: infection, immunity and genetics. Pediatr Infect Dis J. 2005;24(11):998–1004. doi: 10.1097/01.inf.0000183786.70519.fa.
    1. Burns JC, Glode MP. Kawasaki syndrome. Lancet. 2004;364(9433):533–544. doi: 10.1016/S0140-6736(04)16814-1.
    1. Kuo HC, Liang CD, Wang CL, Yu HR, Hwang KP, Yang KD. Serum albumin level predicts initial intravenous immunoglobulin treatment failure in Kawasaki disease. Acta Paediatr. 2010;99(10):1578–1583. doi: 10.1111/j.1651-2227.2010.01875.x.
    1. Park YW, Han JW, Park IS, Kim CH, Cha SH, Ma JS, Lee JS, Kwon TC, Lee SB, Lee HJ, et al. Kawasaki disease in Korea, 2003-2005. Pediatr Infect Dis J. 2007;26(9):821–823. doi: 10.1097/INF.0b013e318124aa1a.
    1. Huang WC, Huang LM, Chang IS, Chang LY, Chiang BL, Chen PJ, Wu MH, Lue HC, Lee CY. Epidemiologic features of Kawasaki disease in Taiwan, 2003-2006. Pediatrics. 2009;123(3):e401–e405. doi: 10.1542/peds.2008-2187.
    1. Nakamura Y, Yashiro M, Uehara R, Oki I, Kayaba K, Yanagawa H. Increasing incidence of Kawasaki disease in Japan: nationwide survey. Pediatr Int. 2008;50(3):287–290. doi: 10.1111/j.1442-200X.2008.02572.x.
    1. Liang CD, Kuo HC, Yang KD, Wang CL, Ko SF. Coronary artery fistula associated with Kawasaki disease. Am Heart J. 2009;157(3):584–588. doi: 10.1016/j.ahj.2008.11.020.
    1. Newburger JW, Takahashi M, Gerber MA, Gewitz MH, Tani LY, Burns JC, Shulman ST, Bolger AF, Ferrieri P, Baltimore RS, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the committee on rheumatic fever, endocarditis and Kawasaki disease, council on cardiovascular disease in the young, American Heart Association. Circulation. 2004;110(17):2747–2771. doi: 10.1161/01.CIR.0000145143.19711.78.
    1. Akagi T, Rose V, Benson LN, Newman A, Freedom RM. Outcome of coronary artery aneurysms after Kawasaki disease. J Pediatr. 1992;121(5 Pt 1):689–694. doi: 10.1016/S0022-3476(05)81894-3.
    1. Shulman ST, De Inocencio J, Hirsch R. Kawasaki disease. Pediatr Clin N Am. 1995;42(5):1205–1222. doi: 10.1016/S0031-3955(16)40059-3.
    1. Yu HR, Kuo HC, Sheen JM, Wang L, Lin IC, Wang CL, Yang KD. A unique plasma proteomic profiling with imbalanced fibrinogen cascade in patients with Kawasaki disease. Pediatr Allergy Immunol. 2009;20(7):699–707. doi: 10.1111/j.1399-3038.2008.00844.x.
    1. Wu MT, Hsieh KS, Lin CC, Yang CF, Pan HB. Images in cardiovascular medicine. Evaluation of coronary artery aneurysms in Kawasaki disease by multislice computed tomographic coronary angiography. Circulation. 2004;110(14):e339. doi: 10.1161/01.CIR.0000143374.80173.EF.
    1. Weng KP, Ho TY, Chiao YH, Cheng JT, Hsieh KS, Huang SH, Ou SF, Liu KH, Hsu CJ, Lu PJ, et al. Cytokine genetic polymorphisms and susceptibility to Kawasaki disease in Taiwanese children. Circ J. 2010;74(12):2726–2733. doi: 10.1253/circj.CJ-10-0542.
    1. Weng KP, Hsieh KS, Ho TY, Huang SH, Lai CR, Chiu YT, Huang SC, Lin CC, Hwang YT, Ger LP. IL-1B polymorphism in association with initial intravenous immunoglobulin treatment failure in Taiwanese children with Kawasaki disease. Circ J. 2010;74(3):544–551. doi: 10.1253/circj.CJ-09-0664.
    1. Weng KP, Hsieh KS, Hwang YT, Huang SH, Lai TJ, Yuh YS, Hou YY, Lin CC, Huang SC, Chang CK, et al. IL-10 polymorphisms are associated with coronary artery lesions in acute stage of Kawasaki disease. Circ J. 2010;74(5):983–989. doi: 10.1253/circj.CJ-09-0801.
    1. Kuo HC, Yu HR, Juo SH, Yang KD, Wang YS, Liang CD, Chen WC, Chang WP, Huang CF, Lee CP, et al. CASP3 gene single-nucleotide polymorphism (rs72689236) and Kawasaki disease in Taiwanese children. J Hum Genet. 2011;56(2):161–165. doi: 10.1038/jhg.2010.154.
    1. Lee KY, Rhim JW, Kang JH. Kawasaki disease: laboratory findings and an immunopathogenesis on the premise of a “protein homeostasis system”. Yonsei Med J. 2012;53(2):262–275. doi: 10.3349/ymj.2012.53.2.262.
    1. Lee KY. A common immunopathogenesis mechanism for infectious diseases: the protein-homeostasis-system hypothesis. Infect Chemother. 2015;47(1):12–26. doi: 10.3947/ic.2015.47.1.12.
    1. Huang YH, Li SC, Huang LH, Chen PC, Lin YY, Lin CC, Kuo HC. Identifying genetic hypomethylation and upregulation of toll-like receptors in Kawasaki disease. Oncotarget. 2017;8(7):11249–11258.
    1. Kuo HC, Wang CL, Liang CD, Yu HR, Chen HH, Wang L, Yang KD. Persistent monocytosis after intravenous immunoglobulin therapy correlated with the development of coronary artery lesions in patients with Kawasaki disease. Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi. 2007;40(5):395–400.
    1. Kuo HC, Yang KD, Liang CD, Bong CN, Yu HR, Wang L, Wang CL. The relationship of eosinophilia to intravenous immunoglobulin treatment failure in Kawasaki disease. Pediatr Allergy Immunol. 2007;18(4):354–359. doi: 10.1111/j.1399-3038.2007.00516.x.
    1. Kuo HC, Wang CL, Liang CD, Yu HR, Huang CF, Wang L, Hwang KP, Yang KD. Association of lower eosinophil-related T helper 2 (Th2) cytokines with coronary artery lesions in Kawasaki disease. Pediatr Allergy Immunol. 2009;20(3):266–272. doi: 10.1111/j.1399-3038.2008.00779.x.
    1. Newburger JW, Takahashi M, Burns JC, Beiser AS, Chung KJ, Duffy CE, Glode MP, Mason WH, Reddy V, Sanders SP, et al. The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med. 1986;315(6):341–347. doi: 10.1056/NEJM198608073150601.
    1. Hsieh KS, Weng KP, Lin CC, Huang TC, Lee CL, Huang SM. Treatment of acute Kawasaki disease: aspirin's role in the febrile stage revisited. Pediatrics. 2004;114(6):e689–e693. doi: 10.1542/peds.2004-1037.
    1. Kuo HC, Chang JC, Kuo HC, Yu HR, Wang CL, Lee CP, Huang LT, Yang KD. Identification of an association between genomic hypomethylation of FCGR2A and susceptibility to Kawasaki disease and intravenous immunoglobulin resistance by DNA methylation array. Arthritis & rheumatology. 2015;67(3):828–836. doi: 10.1002/art.38976.
    1. Kato H, Koike S, Yokoyama T. Kawasaki disease: effect of treatment on coronary artery involvement. Pediatrics. 1979;63(2):175–179.
    1. Saulsbury FT. Comparison of high-dose and low-dose aspirin plus intravenous immunoglobulin in the treatment of Kawasaki syndrome. Clin Pediatr. 2002;41(8):597–601. doi: 10.1177/000992280204100807.
    1. Kuo HC, Lo MH, Hsieh KS, Guo MM, Huang YH. High-dose aspirin is associated with Anemia and does not confer benefit to disease outcomes in Kawasaki disease. PLoS One. 2015;10(12):e0144603. doi: 10.1371/journal.pone.0144603.
    1. Kuo HC, Wang CL, Yang KD, Lo MH, Hsieh KS, Li SC, Huang YH. Plasma prostaglandin E2 levels correlated with the prevention of intravenous immunoglobulin resistance and coronary artery lesions formation via CD40L in Kawasaki disease. PLoS One. 2016;11(8):e0161265. doi: 10.1371/journal.pone.0161265.
    1. Durongpisitkul K, Gururaj VJ, Park JM, Martin CF. The prevention of coronary artery aneurysm in Kawasaki disease: a meta-analysis on the efficacy of aspirin and immunoglobulin treatment. Pediatrics. 1995;96(6):1057–1061.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir